BioMarin commences GALNS Stage 2 research in mucopolysaccharidosis IVA BioMarin Pharmaceutical Inc males dysfunction.

BioMarin commences GALNS Stage 2 research in mucopolysaccharidosis IVA BioMarin Pharmaceutical Inc. today announced the initiation of a Stage 2 research for GALNS in sufferers under five years with mucopolysaccharidosis IVA males dysfunction http://malegra-dxt.org .D., Chief Medical Officer of BioMarin. The principal objective of the Stage 2, open-label, multinational scientific study is to judge the tolerability and safety of infusions of GALNS at a dose of 2.0 mg/kg/week over a 52-week period in ten to fifteen MPS IVA individuals under five years.The campaign promotes existence science organizations within Oregon, Washington, Idaho and Montana and also those in the provinces of Alberta, British Columbia, Saskatchewan and Manitoba.